Starpharma Holdings Limited (SPHRF)
OTCMKTS · Delayed Price · Currency is USD
0.2291
0.00 (0.00%)
At close: Oct 7, 2025
Starpharma Holdings Employees
Starpharma Holdings had 40 employees as of June 30, 2025. The number of employees did not change compared to the previous year.
Employees
40
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$95,883
Profits / Employee
-$163,738
Market Cap
70.72M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 40 | 0 | - |
| Jun 30, 2024 | 40 | -5 | -11.11% |
| Jun 30, 2023 | 45 | -5 | -10.00% |
| Jun 30, 2022 | 50 | 0 | - |
| Jun 30, 2021 | 50 | 5 | 11.11% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Glass House Brands | 374 |
| Elite Pharmaceuticals | 68 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 13 |
| American Oncology Network | 1,914 |
| Silence Therapeutics | 116 |
| Jushi Holdings | 1,234 |
| Nuo Therapeutics | 9 |
Starpharma Holdings News
- 21 days ago - ASX 200 LIVE: ASX climbs, tracking Wall Street; Starpharma inks deal with Roche Group; Reece plans share buyback; Santos receives first gas in Barossa field. - The Australian Financial Review
- 2 years ago - Starpharma: Patience Needed, But A Lot To Like - Seeking Alpha
- 3 years ago - Starpharma presents compelling data in Prostate Cancer at ESMO - PRNewsWire
- 3 years ago - Starpharma signs new DEP® agreement with MSD - PRNewsWire
- 4 years ago - Starpharma releases positive DEP® phase 2 interim results in prostate cancer - PRNewsWire
- 4 years ago - US Patent and Trademark Office grants new patent for DEP® cabazitaxel, one of Starpharma's phase 2 clinical-stage cancer treatments - PRNewsWire
- 4 years ago - Stopping Infection: A Missing Link In The Delta Puzzle? Unloved Investment Opportunity In Starpharma - Seeking Alpha
- 4 years ago - Early-Stage Covid Treatment Prospects: Merck/Ridgeback Bio And Starpharma Lead The Pack - Seeking Alpha